We appreciate the concerns voiced by Dhamne et al [1] about the safety of rTMS for patients with aneurysm clips of any type in response to our letter [2] documenting the safe and beneficial application of this treatment in one of our patients.
In principle it is correct that three types of aversive effects may be potentially induced during rTMS in patients with non-ferromagnetic implanted aneurism clips:
1. Movement of the implant due to Lorenz forces from the TMS coil induced field 2. Heating of the implant due to the induced currents in it 3. Induced current density at the implant that may lead to induced current density at contact points between the implant edges and the tissue which is above desired limits
The exact effect in each case will depend on the detailed parameters of the implant including material, shape, geometry, size, position and orientation relative to the TMS coil. Yet, actual measurements, as done by Rotenberg et al. [3] , have found that "small Ti skull plates are not likely to heat sufficiently to injure surrounding tissue" during a 1 Hz TMS protocol. They also found "minimal displacement of loose Ti plates during simulated rTMS, not out of proportion to that attributable to vibration of the TMS coil". The authors concluded, "as a practical matter it seems highly unlikely that a well-seated screw into cortical bone would move with this weak force". Other studies [4, 5] found minimal heating of various implants with different sizes, orientations and distances, even at an unrealistic distance of 1 cm from the coil surface [4] .
In summary, the accumulated literature suggests that for the vast majority of practical cases, the risks are minimal and rTMS treatment may be safely applied. Given the known and quite significant risks of suicide [6] and disability [7] resulting from treatment resistant depression, and weighing these established risks against the theoretical risks of rTMS in patients with non-ferromagnetic aneurysm clips, (all of which should be discussed with each patient in the informed consent process) we stand by our conclusion that "an absolute contraindication to TMS for all aneurysm clip patients is inappropriate and could deprive treatment-resistant depressed aneurysm patients access to this potentially efficacious therapy." Yet, we agree with the need for systematic ex vivo and in vivo experiments in order to produce a catalog of TMS-safe implants to help enable many potential patients to benefit from TMS.
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